ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut

Trial Profile

ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2015

At a glance

  • Drugs Peanut allergy immunotherapy (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARACHILD
  • Most Recent Events

    • 20 Jun 2013 Complete efficacy and safety results are expected to be published 2013, according to a DBV Technologies media release.
    • 20 Jun 2013 Status changed from active, no longer recruiting to completed, according to 18-month efficacy data published in DBV Technologies media release.
    • 20 Jun 2013 Top-line 6-, 12- and 18-month efficacy data were presented to DBV's Scientific Advisory Board on June 14, 2013, and published in a DBV Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top